The therapeutic efficacy of intravesical agents for bladder cancer (BCa) is frequently constrained by their clearance via urine flushing and periodic bladder emptying, as well as the absence of tumor-targeting capabilities.
Consequently, an effective drug delivery system must possess both tumor-targeting and adhesion properties to overcome these limitations.
